Skip to content

Study · Observational study · n = 98 · 2017

6 results

Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study.

Iwata A, Kanayama M, Oha F, Hashimoto T, Iwasaki N

BMC musculoskeletal disorders7 Apr 2017Cited by 51 (Europe PMC)

PMID28388910 (opens in a new tab)PMCIDPMC5384154 (opens in a new tab)DOI10.1186/s12891-017-1509-1 (opens in a new tab)PepBankPUB-28388910
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundTeriparatide (recombinant human parathyroid hormone 1-34) is increasingly used for the treatment of severe osteoporosis because it stimulates bone formation and may potentially enhance fracture healing. The objective of this study was to investigate the effects of teriparatide versus a bisphosphonate on radiographic outcomes in the treatment of osteoporotic vertebral compression fractures (OVCF).MethodsA total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively. Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group). Except for these medications, the same treatment protocol was applied to both groups. The radiographic assessments included union status, vertebral kyphosis, and mid-vertebral body height. The rates of fracture site surgical intervention were also compared between the two groups. The mean follow-up period was 27 months (median 22.5, range 2 - 75 months).ResultsCox regression analysis showed that TPD reduced the time-to-union (adjusted relative hazard ratio: 1.86, 95% C.I.: 1.21 - 2.83). The union rate at six months after treatment was 89% in the TPD group and 68% in the BP group; the surgical intervention rate was significantly higher in the TPD group (p = 0.026, adjusted odds ratio: 8.15, 95% C.I.: 2.02 - 43.33). The change in local kyphosis was 4.6° in the TPD group and 3.8° in the BP group (p = 0.495, paired t-test). The change of mid-vertebral body height was 4.4 mm in the TPD group and 3.4 mm in the BP group (p = 0.228, paired t-test). Fracture site surgical interventions were not required in the TPD group; however, two patients in the BP group eventually underwent surgical treatment for symptomatic non-union or vertebral collapse.ConclusionsThis retrospective study suggests that teriparatide may enhance fracture healing and improve the union rate in OVCF.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with osteoporotic vertebral fractures, teriparatide was linked to shorter time to union than alendronate.

    In plain wordsIn patients with osteoporotic vertebral fractures, teriparatide was linked to faster union than alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTime to union
    Study

    n = 98

    Comparator
    Alendronate 35 mg weekly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Adjusted relative hazard ratio
    1.86
    time to union
    95% CI of adjusted relative hazard ratio
    1.21 to 2.83
    time to union

    Source sentences

    Summary
    Cox regression analysis showed that TPD reduced the time-to-union (adjusted relative hazard ratio: 1.86, 95% C.I.: 1.21 - 2.83).
    2 context sentences
    Summary · context
    A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively.
    Summary · context
    Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group).
  2. 02HumanObservational studyEfficacy outcome

    In patients with osteoporotic vertebral fractures, teriparatide was linked to higher six-month union rates than alendronate.

    In plain wordsIn patients with osteoporotic vertebral fractures, teriparatide was linked to more fracture union than alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUnion at six months
    Study

    n = 98

    Comparator
    Alendronate 35 mg weekly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Union rate
    89%
    teriparatide
    Union rate
    68%
    alendronate

    Source sentences

    Summary
    The union rate at six months after treatment was 89% in the TPD group and 68% in the BP group;
    2 context sentences
    Summary · context
    A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively.
    Summary · context
    Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group).
  3. 03HumanObservational studySafety outcome

    In patients with osteoporotic vertebral fractures, one result links teriparatide to higher surgical intervention rates than alendronate, conflicting with the later result.

    In plain wordsIn patients with vertebral fractures, one abstract result links teriparatide to more surgery than alendronate, but another contradicts it.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSurgical intervention: conflicting report
    Study

    n = 98

    Comparator
    Alendronate 35 mg weekly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Adjusted odds ratio
    8.15
    surgical intervention, teriparatide versus alendronate
    95% CI of adjusted odds ratio
    2.02 to 43.33
    surgical intervention, teriparatide versus alendronate

    Source sentences

    Summary
    the surgical intervention rate was significantly higher in the TPD group (p = 0.026, adjusted odds ratio: 8.15, 95% C.I.: 2.02 - 43.33).
    2 context sentences
    Summary · context
    A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively.
    Summary · context
    Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group).
  4. 04HumanObservational studyEfficacy outcome

    In patients with osteoporotic vertebral fractures, local kyphosis change did not differ significantly between teriparatide and alendronate.

    In plain wordsIn patients with osteoporotic vertebral fractures, kyphosis change did not differ significantly between teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLocal kyphosis change
    Study

    n = 98

    Comparator
    Alendronate 35 mg weekly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Change in local kyphosis
    4.6°
    teriparatide group
    Change in local kyphosis
    3.8°
    alendronate group

    Source sentences

    Summary
    The change in local kyphosis was 4.6° in the TPD group and 3.8° in the BP group (p = 0.495, paired t-test).
    2 context sentences
    Summary · context
    A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively.
    Summary · context
    Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group).
  5. 05HumanObservational studyEfficacy outcome

    In patients with osteoporotic vertebral fractures, vertebral height change did not differ significantly between teriparatide and alendronate.

    In plain wordsIn patients with osteoporotic vertebral fractures, vertebral height change did not differ significantly between teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeMid-vertebral body height change
    Study

    n = 98

    Comparator
    Alendronate 35 mg weekly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Change in mid-vertebral body height
    4.4 mm
    teriparatide group
    Change in mid-vertebral body height
    3.4 mm
    alendronate group

    Source sentences

    Summary
    The change of mid-vertebral body height was 4.4 mm in the TPD group and 3.4 mm in the BP group (p = 0.228, paired t-test).
    2 context sentences
    Summary · context
    A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively.
    Summary · context
    Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group).
  6. 06HumanObservational studySafety outcome

    In patients with osteoporotic vertebral fractures, another result reports no surgery with teriparatide versus surgery with alendronate, contradicting the earlier result.

    In plain wordsIn patients with vertebral fractures, another abstract result reports no surgery with teriparatide versus surgery with alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture site surgical intervention
    Study

    n = 98

    Comparator
    Alendronate 35 mg weekly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with fracture site surgical intervention
    2 patients
    alendronate group

    Source sentences

    Summary
    Fracture site surgical interventions were not required in the TPD group; however, two patients in the BP group eventually underwent surgical treatment for symptomatic non-union or vertebral collapse.
    2 context sentences
    Summary · context
    A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively.
    Summary · context
    Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.